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Potassium Disturbances and Risk of Ventricular Fibrillation Among
Patients With ST-Segment–Elevation Myocardial Infarction
Mia Ravn Jacobsen, MD;* Reza Jabbari, MD, PhD;* Charlotte Glinge, MD, PhD; Niels Kjær Stampe, MD; Jawad Haider Butt, MD;
Paul Blanche, PhD; Jacob Lønborg, MD, PhD, DMSc; Olav Wendelboe Nielsen, MD, PhD, DMSc; Lars Køber, MD, DMSc;
Christian Torp-Pedersen, MD, DMSc; Frants Pedersen, MD, PhD; Jacob Tfelt-Hansen, MD, DMSc; Thomas Engstrøm, MD, PhD, DMSc
Background-—Potassium disturbances per se increase the risk of ventricular fibrillation (VF). Whether potassium disturbances in
the acute phase of ST-segment–elevation myocardial infarction (STEMI) are associated with VF before primary percutaneous
coronary intervention (PPCI) is uncertain.
Methods and Results-—All consecutive STEMI patients were identified in the Eastern Danish Heart Registry from 1999 to 2016.
Comorbidities and medication use were assessed from Danish nationwide registries. Potassium levels were collected immediately
before PPCI start. Multivariate logistic models were performed to determine the association between potassium and VF. The main
analysis included 8624 STEMI patients of whom 822 (9.5%) had VF before PPCI. Compared with 6693 (77.6%) patients with
normokalemia (3.5–5.0 mmol/L), 1797 (20.8%) patients with hypokalemia (<3.5 mmol/L) were often women with fewer
comorbidities, whereas 134 (1.6%) patients with hyperkalemia (>5.0 mmol/L) were older with more comorbidities. After
adjustment, patients with hypokalemia and hyperkalemia had a higher risk of VF before PPCI (odds ratio 1.90, 95% CI 1.57–2.30,
P<0.001) and (odds ratio 3.36, 95% CI 1.95–5.77, P<0.001) compared with normokalemia, respectively. Since the association may
reflect a post-resuscitation phenomenon, a sensitivity analysis was performed including 7929 STEMI patients without VF before
PPCI of whom 127 (1.6%) had VF during PPCI. Compared with normokalemia, patients with hypokalemia had a significant
association with VF during PPCI (odds ratio 1.68, 95% CI 1.01–2.77, P=0.045) after adjustment.
Conclusions-—Hypokalemia and hyperkalemia are associated with increased risk of VF before PPCI during STEMI. For hypokalemia,
the association may be independent of the measurement of potassium before or after VF. ( J Am Heart Assoc. 2020;9:e014160.
DOI: 10.1161/JAHA.119.014160.)
Key Words: potassium disturbances • ST-segment–elevation myocardial infarction • ventricular fibrillation
C oronary artery disease leading to myocardial infarction(MI) is the leading cause of sudden cardiac death.1–4
Ventricular fibrillation (VF) complicating ST-segment–elevation
myocardial infarction (STEMI) occurs in  10% of patients5,6
and remains a challenge for physicians as VF may be the first
symptom of underlying cardiovascular disease.
Potassium disturbances are one of the most common
electrolyte abnormalities.7 The role of potassium disturbances
in the setting of MI has been studied, with a higher frequency of
ventricular arrhythmias observed for low potassium levels
(typically <3.5 mmol/L).8–10 Although these findings highlight
the importance of potassium disturbances as a risk factor for
VF amongMI patients,11 many of these studies were conducted
in a time before the era of PPCI,8–10 included a relatively small
number of patients,8,10 and defined the outcome as cardiac
arrest; therefore, a proportion of the arrests may not have been
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VF.12 Furthermore, none of these studies distinguished
between STEMI and non-STEMI patients. Both conditions arise
from the same pathogenesis,13 but may not be comparable in
risk assessment for VF as the burden of VF is lower among non-
STEMI patients (2%).14,15
Recently, in a large cohort of MI patients, a U-shaped
relationship between post-admission potassium levels and in-
hospital mortality was observed and increased rates of
cardiac arrest during hospitalization demonstrated for the
lowest (<3.0 mmol/L) and highest (≥5.0 mmol/L) potassium
levels.12 However, this study was underpowered in regard to
the number of VF, possibly because of misclassification of the
cardiac arrest diagnosis. While recent studies have demon-
strated prognostic effects of potassium disturbances in the
inpatient setting,12,16 no study has investigated the risk of
potassium disturbances for developing VF in the early, and
potentially modifiable, ischemic phase of an acute MI (before
PPCI).
The aim of this study was to determine the association
between potassium disturbances and the risk of VF before
PPCI among STEMI patients. Since potassium disturbances
may reflect a post-resuscitation phenomenon, a sensitivity
analysis was performed including STEMI patients with VF
during PPCI who had potassium measurements before PPCI
and, thereby, before VF.
Methods
Anonymized data created for the study are available in a
persistent repository.
Study Design and Data Sources
This single-center cohort study included patients aged
≥18 years with STEMI (Figure 1). Clinical data from the Eastern
Danish Heart Registry were used. This registry comprises
detailed clinical, angiographic, and procedural characteristics
on all consecutive STEMI patients who underwent cardiac
catheterization and coronary revascularization at Copenhagen
University Hospital, Rigshospitalet since October 21, 1999.
These data have been registered routinely by all operators and
assistants in the catherization laboratory during percutaneous
coronary intervention. Until June 1, 2011 Rigshospitalet had a
catchment area for PPCI of 1.7 million inhabitants (30% of the
entire Danish population), and from then on Rigshospitalet has
covered all eastern Denmark corresponding to 2.5 million (45%
of the entire Danish population).5
Data were linked to Danish nationwide administrative
registries via the Civil Registration Number. All residents in
Denmark receive a unique, personal, and permanent Civil
Registration Number, which enables individual linkage of
nationwide healthcare-related registries unambiguously. Infor-
mation on vital status and the date of birth was retrieved from
the Danish Civil Registration System.17 The Danish National
Patient Register holds information on all hospital admissions
and outpatient contacts according to the International Clas-
sification of Disease, Eighth and Tenth Revisions (ICD-8 and
ICD-10),18 and the date of admission, discharge, and
diagnoses was retrieved for every patient before the STEMI
index admission (Table S1). Information on dispensed
medicine 3 months before the STEMI index was collected
from the Danish National Prescription Registry, which holds
information on all dispensed medical prescriptions from
Danish pharmacies based on the Anatomical Therapeutic
Chemical System codes including type of drug, dispensing
date, strength, and quantity of all claimed drug prescriptions
(Table S2).19 Hypertension, diabetes mellitus, and hyperc-
holesterolemia were identified according to diagnosis either
from hospital admissions or outpatient contacts and in
addition from dispensed medication (antihypertensives, antidi-
abetics, and cholesterol-lowering drugs, respectively)
3 months before STEMI index.
Data on blood levels were obtained from an electronic
laboratory database with several blood samples and their
exact time of measurement. Blood samples immediately
before PPCI were selected. Potassium levels were categorized
in 3 preselected intervals: hypokalemia <3.5 mmol/L, normo-
kalemia 3.5–5.0 mmol/L, and hyperkalemia >5.0 mmol/L.
Clinical Perspective
What Is New?
• ST-segment–elevation myocardial infarction (STEMI) patients
with hypo- and hyperkalemia had a higher risk of ventricular
fibrillation (VF) before primary percutaneous coronary inter-
vention (PPCI) compared with normokalemia, but the asso-
ciation may reflect a post-resuscitation phenomenon as
potassium was measured immediately before PPCI, hence
after VF.
• For STEMI patients with in-hospital VF before PPCI with a
short time window between potassium measurement and
VF, hypokalemia remained associated with VF compared
with normokalemia.
• Among STEMI patients without VF before PPCI who had
potassium measurements immediately before PPCI, hypo-
kalemia was associated with VF during PPCI.
What Are the Clinical Implications?
• Potassium disturbances among STEMI patients may
increase the risk of VF before PPCI and subsequent death
during acute ischemia.
• Further studies are needed to determine if correcting
potassium disturbances will reduce the risk of VF before
PPCI among patients with STEMI.
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Study Population
To qualify for the study, patients had to have symptoms
lasting ≤12 hours and acute ST-segment elevation on an ECG.
All patients underwent angiography and subsequent PPCI, and
only the first admission to PPCI in patients with multiple
admissions was considered.
The primary outcome was VF or sustained pulseless
ventricular tachycardia (VT) (≥30 seconds and/or clinical
cardiac arrest) within 12 hours of symptoms and before
catheter insertion for PPCI. All medical reports and
discharge summaries were reviewed to verify the VF
diagnosis. Both out-of-hospital and in-hospital cardiac
arrest (but before PPCI) patients were included. Patients
with out-of-hospital cardiac arrest were included upon
admission to the PCI-center after resuscitation by emer-
gency medical service personnel. Patients with VF during
PPCI were excluded from the main analysis as the
arrhythmogenesis may be different and related to catheter
maneuvers.
Since potassium levels were measured after VF but
before PPCI, a sensitivity analysis was conducted to
examine the association between potassium levels before
VF and the risk of developing VF. STEMI patients with VF
before PPCI were excluded and patients with VF during
PPCI were identified, and they had potassium measure-
ments immediately before PPCI and, thereby, before VF.
Statistical Analysis
The baseline and angiographic characteristics are presented
as the median and interquartile range or proportion for the
potassium groups. Statistical significance related to the
descriptive differences were computed using the Wilcoxon
rank-sum test for continuous variables and the Chi-square
test (or Fisher exact test when appropriate) for categorical
variables. A 2-tailed P≤0.05 was considered statistically
significant.
Logistic regression models were constructed to examine
whether potassium disturbances were independent risk
factors for VF among STEMI patients. Adjusted odds ratios
(OR) and accompanying 95% confidence intervals (CI) were
computed to estimate the associations. Multivariate logistic
models were performed by including any covariate preceding
the STEMI that is known to increase the risk of VF: age, sex,
previous history of chest pain, smoking, hypertension, prior
myocardial infarction, congestive heart failure, atrial fibrilla-
tion, acute creatinine levels, Killip class at admission, culprit
lesion, and preprocedural thrombolysis in myocardial infarc-
tion (TIMI) flow.5,6,20–22 Peripheral vascular disease and
diabetes mellitus were included in the model, as these
comorbidities were independently associated with VF in this
cohort. Smoking and Canadian Cardiovascular Society grading
of angina pectoris were later removed from the model
because of a large amount of missing information of 12% and
 
All STEMI patients with potassium measurements immediately before PPCI (n=8624) 
Excluded: 
Non-Danish citizens (n=180) 
Patients with symptoms >12 hours before PPCI (n=384) 
Patients with missing date of PPCI (n=5) 
Patients with missing potassium measurement (n=126) 
Patients with ventricular fibrillation during PPCI (n=127) 
Hypokalemia <3.5 mmol/L 
 (n=1797) 
All STEMI patients admitted to PPCI at Rigshospitalet from 1999-2016 (n=9446) 
Normokalemia [3.5-5.0 mmol/L] 
 (n=6693) 
Hyperkalemia >5.0 mmol/L 
 (n=134) 
Figure 1. Flowchart illustrating the selection of patients with STEMI admitted to primary percutaneous
coronary intervention at Rigshospitalet from 1999 to 2016. PPCI indicates primary percutaneous coronary
intervention; STEMI, ST-segment–elevation myocardial infarction.
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Table 1. Characteristics of Patients With STEMI Who Had Potassium Measurements Immediately Before Primary Percutaneous
Coronary Intervention
Variables
Normokalemia
3.5 to 5.0 mmol/L
(n=6693)
Hypokalemia
<3.5 mmol/L
(n=1797)
P Value
Hypokalemia Vs
Normokalemia
Hyperkalemia
>5.0 mmol/L
(n=134)
P Value
Hyperkalemia Vs
Normokalemia
Male sex, n (%) 5145 (76.9) 1178 (65.6) <0.001 99 (73.9) 0.50
Median age, y [IQR] 63.0 [53.9, 71.9] 62.7 [53.5, 72.0] 0.57 68.5 [60.2, 76.9] <0.001
Categorical age, n (%)
<50 y 1070 (16.0) 302 (16.8) 0.62 11 (8.2) 0.003
50 to 80 y 4908 (73.3) 1312 (73.0) 99 (73.9)
≥80 y 715 (10.7) 183 (10.2) 24 (17.9)
Body mass index (BMI), kg/m2
BMI ≥25, n (%) 3270 (62.3) 897 (64.5) 0.14 59 (63.4) 0.90
Smoking, n (%)
Current 3069 (52.3) 762 (48.4) <0.001 45 (47.4) 0.62
Past 1480 (25.2) 382 (24.3) 27 (28.4)
Never 1318 (22.5) 430 (27.3) 23 (24.2)
Canadian cardiovascular society grading of angina pectoris, n (%)
Class I to II 735 (12.1) 182 (11.1) 0.25 15 (14.7) 0.50
Class III to IV 587 (9.7) 144 (8.8) 7 (6.9)
No angina 4753 (78.2) 1316 (80.1) 80 (78.4)
Comorbidities, n (%)
Diabetes mellitus 789 (11.8) 157 (8.7) <0.001 41 (30.6) <0.001
Hypertension 1692 (25.3) 667 (37.1) <0.001 62 (46.3) <0.001
Hypercholesterolemia 1220 (18.2) 310 (17.3) 0.36 35 (26.1) 0.026
Peripheral vascular disease 284 (4.2) 45 (2.5) <0.001 14 (10.4) 0.001
Family history of ischemic
heart disease
1719 (32.5) 466 (33.5) 0.51 18 (28.6) 0.60
Ischemic heart disease 1356 (20.3) 335 (18.6) 0.14 39 (29.1) 0.016
Prior myocardial infarction 827 (12.4) 177 (9.8) 0.004 30 (22.4) <0.001
Congestive heart failure 312 (4.7) 64 (3.6) 0.05 14 (10.4) 0.004
Atrial fibrillation 290 (4.3) 71 (4.0) 0.52 20 (14.9) <0.001
Stroke 310 (4.6) 72 (4.0) 0.28 9 (6.7) 0.35
Chronic kidney disease 194 (2.9) 39 (2.2) 0.11 17 (12.7) <0.001
Liver disease 87 (1.3) 29 (1.6) 0.37 ≤3 (≤2.2) 1.00
Outcome, n (%)
Ventricular fibrillation before PPCI 548 (8.2) 242 (13.5) <0.001 32 (23.9) <0.001
Pharmacotherapy, n (%)
Diuretics (combinational) 265 (4.0) 187 (10.4) <0.001 5 (3.7) 1.00
Loop diuretics 292 (4.4) 82 (4.6) 0.76 19 (14.2) <0.001
Thiazides 357 (5.3) 256 (14.2) <0.001 8 (6.0) 0.90
Spironolactone 64 (1.0) 13 (0.7) 0.43 9 (6.7) <0.001
Potassium supplements 210 (3.1) 98 (5.5) <0.001 13 (9.7) <0.001
Renin-angiotensin-system
blockers
1198 (17.9) 386 (21.5) <0.001 37 (27.6) 0.005
Continued
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9%, respectively. Use of diuretic medication (loop diuretics,
combinational diuretics, thiazides, and spironolactone)
3 months before STEMI index was also included. Prior use
of antiarrhythmic therapy (class I and III agents) may reduce
the risk of VF in the setting of STEMI. However, since <0.2% of
patients were treated with antiarrhythmic drugs 3 months
before STEMI index, treatment with antiarrhythmic drugs was
not included in the model. Finally, maximum troponin-T levels
measured during hospitalization (within 3 days after STEMI
index) was included.
Additional analysis adjusted for age, sex, and acute crea-
tinine levels was conducted to illustrate the relationship
between potassium and VF before PPCI. The same potassium
measurements and comparison groups were used but the
hypokalemia group was divided into severe (2.1–2.7 mmol/L)
and mild hypokalemia (2.8–3.4 mmol/L). The hyperkalemia
group had too few patients to perform further substratification.
Furthermore, a subpopulation of STEMI patients with in-
hospital VF before PPCI was studied (excluding STEMI
patients with out-of-hospital VF). In this way, the time window
between VF and potassium measurement would be short and
the VF anticipated to be treated immediately. A logistic
regression model was performed to evaluate the association
between potassium disturbances and risk of in-hospital VF
before PPCI adjusted for age, sex, and acute creatinine levels.
Finally, a logistic regression model was conducted in the
sensitivity analysis to emphasize the association between
potassium disturbances and VF during PPCI adjusted for age,
sex, cardiovascular comorbidities (hypertension, prior myocar-
dial infarction, congestive heart failure, atrial fibrillation,
diabetes mellitus, and peripheral vascular disease), acute
creatinine levels, maximum troponin-T levels, Killip class,
culprit lesion, preprocedural TIMI flow, and use of diuretic
medication.
Analyses were performed using SAS (version 9.4, SAS
Institute, Cary, NC, USA) and RStudio (version 3.4).
Ethics Approval
The study was approved by the Danish Data Protection
Agency (2007-58-0015/GEH-2014-014 and I-suite number:
02732). Registers were available in an anonymous setup;
individual patients were not identifiable because the Civil
Registration Numbers were encrypted. Approval from the
Danish Patient Safety Authority was received to gain
information on medical reports and discharge summaries
(No. 3-3013-2277/1). In Denmark ethical approval is not
required for retrospective register-based studies.
Results
Out of 9446 consecutively enrolled STEMI patients, 8624
(91%) STEMI patients with potassium measurements immedi-
ately before PPCI were included, of whom 1797 (20.8%) had
hypokalemia (<3.5 mmol/L), 6693 (77.6%) had normokalemia
[3.5–5.0 mmol/L], and 134 (1.6%) had hyperkalemia
(>5.0 mmol/L). The distribution of potassium approached
that of a normal distribution with a mean of 3.8 mmol/L (SD:
0.5) (Figure S1).
Clinical Characteristics
Among the 8624 included STEMI patients, 822 (9.5%) had VF
before PPCI. Of the 822 STEMI with VF, 49 (6%) developed
sustained pulseless VT. The majority had out-of-hospital
Table 1. Continued
Variables
Normokalemia
3.5 to 5.0 mmol/L
(n=6693)
Hypokalemia
<3.5 mmol/L
(n=1797)
P Value
Hypokalemia Vs
Normokalemia
Hyperkalemia
>5.0 mmol/L
(n=134)
P Value
Hyperkalemia Vs
Normokalemia
Beta-blockers 827 (12.4) 208 (11.6) 0.39 25 (18.7) 0.040
Anti-adrenergic drugs 57 (0.9) 16 (0.9) 0.99 0 (0.0) 0.55
Calcium channel blockers 728 (10.9) 335 (18.6) <0.001 20 (14.9) 0.18
Antidiabetics 602 (9.0) 113 (6.3) <0.001 33 (24.6) <0.001
Statins 940 (14.0) 224 (12.5) 0.09 25 (18.7) 0.16
Antiarrhythmic drugs class I and III 8 (0.1) ≤3 (≤1.7) 0.74 ≤3 (≤2.2) 0.003
Blood samples
Acute creatinine, lmol/L [IQR] 78.0 [66.0, 94.0] 76.0 [64.0, 91.0] <0.001 126.5 [97.0, 168.5] <0.001
Troponin-T max, ng/L [IQR] 3775 [1500, 7490] 3560 [1360, 7520] 0.10 5110 [1700, 13 300] 0.007
Time from symptom to
troponin-T max, h [IQR]
13.8 [9.6, 18.0] 13.9 [9.8, 18.7] 0.15 15.5 [9.1, 21.3] 0.23
Missing: BMI 22%, smoking 13%, family history of ischemic heart disease 22%, Canadian Cardiovascular Society class 9%, acute creatinine 7%, troponin-T max 20%, and time from
symptoms to troponin-T max 20%. BMI indicates body mass index; IQR, interquartile range. STEMI indicates ST-segment–elevation myocardial infarction.
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cardiac arrest (77%) and 21% had in-hospital cardiac arrest
(2% with missing information).
Baseline and angiographic characteristics are summarized
in Tables 1 and 2. Compared with normokalemia, patients
with hypokalemia were often women, smoked less, had fewer
cardiovascular comorbidities, and lower acute creatinine
levels. More often they had hypertension, used cardioactive
drugs, had left anterior descending artery as culprit, and a
preprocedural TIMI flow 0 to I.
Patients with hyperkalemia were older, had more cardio-
vascular comorbidities, used more cardioactive and antidia-
betic drugs, were in Killip class >I, had pre- and post-procedural
TIMI flow 0 to I, and increased levels of acute creatinine and
troponin-T max compared with patients with normokalemia.
Multivariate Analysis
Younger age, male sex, atrial fibrillation, Killip class >I, left
anterior descending artery as culprit, and preprocedural
TIMI flow 0 to I were all independent risk factors for VF,
whereas prior myocardial infarction and diabetes mellitus
were independently associated with reduced risk of VF
(Table 3). Hypokalemia (OR 1.90, 95% CI 1.57–2.30,
P<0.001) and hyperkalemia (OR 3.36, 95% CI 1.95–5.77,
P<0.001) were associated with VF compared with normo-
kalemia after adjusting for age, sex, cardiovascular comor-
bidities (hypertension, prior myocardial infarction,
congestive heart failure, atrial fibrillation, diabetes mellitus,
and peripheral vascular disease), acute creatinine levels,
maximum troponin-T levels, Killip class, culprit lesion,
preprocedural TIMI flow, and use of diuretic medication
(loop diuretics, combinational diuretics, thiazides, and
spironolactone) (Figure 2).
A U-shaped relationship between potassium levels and VF
before PPCI was found with the highest risk for VF among
patients with severe hypokalemia [2.1–2.7 mmol/L] com-
pared with normokalemia after adjusting for age, sex, and
acute creatinine levels (Figure 3).
Table 2. Angiographic and Procedural Characteristics of Patients With STEMI Who Had Potassium Measurements Immediately
Before Primary Percutaneous Coronary Intervention
Variables
Normokalemia
3.5 to 5.0 mmol/L
(n=6693)
Hypokalemia
<3.5 mmol/L
(n=1797)
P Value
Hypokalemia Vs
Normokalemia
Hyperkalemia
>5.0 mmol/L
(n=134)
P Value
Hyperkalemia Vs
Normokalemia
Time from symptom onset to PPCI, min [IQR] 188 [132–280] 145 [108–230] <0.001 198 [138–330] 0.21
Preprocedural LVEF, n (%)
≤35% 346 (26.1) 107 (28.2) 0.44 27 (64.3) <0.001
Infarct location, n (%)
Anterior 2773 (44.6) 808 (48.6) 0.004 45 (42.1) 0.67
Non-anterior 3445 (55.4) 856 (51.4) 62 (57.9)
Culprit lesion, n (%)
LAD 2937 (44.1) 864 (48.4) 0.006 62 (46.6) 0.84
RCA 2748 (41.3) 683 (38.2) 53 (39.8)
LCX 970 (14.6) 239 (13.4) 18 (13.5)
Killip class, n (%)
I 5841 (91.9) 1572 (91.1) 0.17 79 (64.8) <0.001
II 284 (4.5) 94 (5.4) 10 (8.2)
III 87 (1.4) 28 (1.6) 5 (4.1)
IV 146 (2.3) 31 (1.8) 28 (23.0)
Preprocedural TIMI flow, n (%)
TIMI 0 to I 4245 (64.0) 1209 (68.3) <0.001 104 (78.8) <0.001
TIMI II to III 2392 (36.0) 562 (31.7) 28 (21.2)
Postprocedural TIMI flow, n (%)
TIMI 0 to I 163 (2.5) 45 (2.5) 0.92 11 (8.3) <0.001
TIMI II to III 6462 (97.5) 1727 (97.5) 121 (91.7)
Missing: Time from symptom to procedure 15%, LVEF 80%, and Infarct location 7%. IQR indicates interquartile range; LAD, left anterior descending artery; LCX, left circumflex artery; LVEF,
left ventricular ejection fraction; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery, STEMI, ST-segment–elevation myocardial infarction; TIMI, thrombolysis in
myocardial infarction.
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Finally, a subpopulation of patients with in-hospital VF
before PPCI was studied. Among the 7977 included STEMI
patients without out-of-hospital VF, 175 (2.2%) had in-hospital
VF before PPCI. Hypokalemia (n=1616) (OR 2.23, 95% CI
1.60–3.11, P<0.001) was associated with VF compared with
normokalemia after adjusting for age, sex, and acute
creatinine level (Table S3). For hyperkalemia (n=104) (OR
0.79, 95% CI 0.17–3.61, P=0.76), no significant association
was found (Table S3).
Sensitivity Analysis
The sensitivity analysis included 7929 STEMI patients without
VF before PPCI of whom 127 (1.6%) had VF during PPCI.
Baseline and angiographic characteristics are shown in
supplementary Tables S4 and S5. Patients with hypokalemia
were often women, smoked less, had fewer cardiovascular
comorbidities (except for hypertension), used more antihy-
pertensive drugs, and had lower acute creatinine levels,
whereas patients with hyperkalemia were older, had more
cardiovascular comorbidities, and used more medications
compared with normokalemia. Compared with normokalemia,
patients with hypokalemia had an OR of 1.68 (95% CI 1.01–
2.77, P=0.045) and patients with hyperkalemia had an OR of
3.23 (95% CI 0.99–10.50, P=0.05) for VF after adjustment
(Figure 4, and Table S6).
Discussion
In this study with consecutive data collected from 1999 to
2016, 8624 STEMI patients were enrolled, of whom 822
(9.5%) developed VF before PPCI. Increased risk of VF before
PPCI was demonstrated for patients with hypokalemia
[<3.5 mmol/L] and hyperkalemia [>5.0 mmol/L], and a U-
shaped relationship between potassium levels and VF before
PPCI was found, with the highest risk of VF among patients
with severe hypokalemia [2.1–2.7 mmol/L].
Whereas patients with VF before PPCI had potassium
measurements after VF that may be disturbed by the VF itself,
patients with VF during PPCI had potassium measurements
before VF. Importantly, hypokalemia was associated with
Table 3. A Logistic Regression Model of the Risk of VF Before PPCI in STEMI Patients
Variables Contrast Odds Ratio 95% CI P Value
Blood samples
Hyperkalemia Normokalemia 3.36 1.95 to 5.77 <0.001
Hypokalemia Normokalemia 1.90 1.57 to 2.30 <0.001
Creatinine 10 lmol/L of increase 1.00 1.00 to 1.01 <0.001
Troponin-T max 1000 ng/L of increase 1.01 1.00 to 1.02 0.24
Age
<50 y of age ≥80 y of age 4.17 2.62 to 6.63 <0.001
50 to 80 y of age ≥80 y of age 3.94 2.59 to 5.99 <0.001
Sex Men vs women 1.29 1.04 to 1.60 0.020
Hypertension Yes vs no 1.14 0.89 to 1.45 0.29
Prior myocardial infarction Yes vs no 0.73 0.53 to 1.00 0.048
Congestive heart failure Yes vs no 0.60 0.35 to 1.02 0.06
Atrial fibrillation Yes vs no 1.62 1.08 to 2.42 0.019
Diabetes mellitus Yes vs no 0.55 0.40 to 0.75 <0.001
Peripheral vascular disease Yes vs no 1.72 1.14 to 2.59 0.009
Killip class >I at admission Killip class I 2.95 2.30 to 3.77 <0.001
Culprit LAD vs non-LAD 1.58 1.32 to 1.87 <0.001
Preprocedural TIMI flow TIMI 0 to I vs II to III 1.33 1.10 to 1.62 0.004
Loop diuretics Yes vs no 1.10 0.68 to 1.78 0.70
Combinational diuretics Yes vs no 0.82 0.54 to 1.23 0.33
Thiazides Yes vs no 1.05 0.74 to 1.49 0.80
Spironolactone Yes vs no 1.56 0.65 to 3.71 0.32
LAD indicates left anterior descending artery; PPCI, primary percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; TIMI, thrombolysis in myocardial
infarction; VF, ventricular fibrillation.
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increased risk of VF during PPCI. Hence, the association
between hypokalemia and VF may be independent of the
measurement of potassium before or after VF.
To the best of our knowledge, this is the first comprehen-
sive study to investigate the association between potassium
disturbances and the risk of VF before PPCI. In addition to an
increased risk for VF in patients with severe hypo- and
hyperkalemia, our data suggested that patients with mild
hypokalemia also had a higher risk for VF. Mild hypokalemia
[2.8–3.4 mmol/L] is not always considered harmful in daily
clinical practice and may not be a target for immediate
intervention. These findings suggest that maintenance of
potassium levels between 3.5–5.0 mmol/L is advisable as
currently recommended by practice guidelines in patients with
AMI based on non-randomized trials.23
Recently, Goyal and colleagues12 investigated the cor-
relation between mean post-admission potassium levels
and mortality rates among MI patients. They found a U-
shaped relationship between in-hospital mortality and
potassium levels with the lowest risk between 3.5 and
<4.5 mmol/L. Compared with mortality risk, they observed
a relatively more flattened association between potassium
levels and the risk of cardiac arrest during hospitalization.
They found a significant increase in the risk of cardiac
arrest for patients with hypokalemia <3.0 mmol/L after
adjustment for age, sex, and glomerular filtration rate at
admission. However, the number of events (cardiac arrest
because of any cause) in the hypokalemia group was low
(n=5), perhaps because of misclassification of the cardiac
arrest diagnosis.
In this study, patients with hypokalemia had a lower
burden of cardiovascular comorbidities, whereas hypertension
and use of cardioactive drugs were more frequent compared
with normokalemia, eg, thiazides which can cause pro-
nounced hypokalemia during MI.24 Importantly, after adjusting
for use of any diuretics, the risk estimates for both hypo- and
hyperkalemia remained unchanged.
Both endogenous epinephrine attributable to the cardiac
arrest and exogenous epinephrine administered during resus-
citation can transiently cause hypokalemia and decrease
potassium by as much as 1 mmol/L.25 Since potassium was
measured after VF in the main analysis, hypokalemia may
reflect a post-resuscitation phenomenon. However, in the
sensitivity analysis, increased risk of VF was demonstrated for
patients with hypokalemia measured before VF. Thus, the
association between hypokalemia and VF may be independent
of the measurement of potassium before or after VF.
Moreover, additional analysis was performed including 175
Figure 2. Potassium disturbances associated with ventricular fibrillation before primary percutaneous coronary intervention among
patients with STEMI who had potassium measurements immediately before primary percutaneous coronary intervention. PPCI
indicates primary percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; VF, ventricular fibrillation.
Figure 3. Association between potassium levels and risk of
ventricular fibrillation before primary percutaneous coronary
intervention among patients with STEMI. The x axis shows
potassium measurements (mmol/L) immediately before primary
percutaneous coronary intervention. The y axis shows the odds
ratio of ventricular fibrillation before primary percutaneous
coronary intervention adjusted for age, sex, and acute creatinine
level. Each point indicates the odds ratio corresponding to the
median of potassium for 4 potassium intervals: severe
hypokalemia [2.1–2.7 (mmol/L); 4.61, 95% CI 2.77–7.42], mild
hypokalemia [2.8–3.4 (mmol/L); odds ratio=1.76, 95% CI 1.48–
2.09], normokalemia [3.5–5.0 (mmol/L); reference], hyper-
kalemia [5.1–7.4 (mmol/L); odds ratio 2.76, 95% CI 1.74–
4.26]. The horizontal bars indicate the range of the potassium
levels. The vertical bars indicate the 95% CI of the odds ratios.
PPCI indicates primary percutaneous coronary intervention;
STEMI, ST-segment–elevation myocardial infarction; VF, ventric-
ular fibrillation.
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patients with VF before PPCI in whom VF occurred after
admission to the hospital. In this way, the time window
between VF and potassium measurement would be short and
the VF anticipated to be treated immediately. Compared with
patients with normokalemia, patients with hypokalemia had
increased risk of in-hospital VF before PPCI after adjusting for
age, sex, and acute creatinine level. Patients with hyper-
kalemia had no increased risk of VF possibly because of lack
of power (n≤3).
Patients with hyperkalemia had more cardiovascular
comorbidities and higher use of various medications. Hence,
hyperkalemia may be a marker of comorbidities and polyphar-
macy. Furthermore, acidosis following cardiac arrest or
cardiogenic shock stimulates cellular efflux of potassium
leading to hyperkalemia,26 and patients with hyperkalemia
were often Killip class >I. As epinephrine can lead to
hypokalemia, a larger fraction of patients with hyperkalemia
would be found in the normokalemia group. Hence, the risk
estimates for VF among patients with hyperkalemia may be
even greater than reported herein.
Prior myocardial infarction and diabetes mellitus was
independently associated with reduced risk of VF before PPCI
among patients with STEMI. This is a departure from our usual
understanding.20,27 A possible explanation for this is that
these patients may have more severe coronary artery disease
which may influence the formation of collateral blood flow.
However, data are conflicting whether diabetes mellitus
enhance or impair the formation of collateral blood flow.28,29
Furthermore, recent studies suggest that the increase in risk
of sudden cardiac arrest among patients with diabetes
mellitus is not specific for sudden cardiac arrest, as diabetes
mellitus also is associated with a similar increase in risk of
death because of fatal (non-sudden cardiac arrest) coronary
heart disease, and non-fatal myocardial infarction.30,31 Hence,
patients with diabetes mellitus may not be at greater risk of
VF in the setting of STEMI. On the other hand, as patients who
do not survive to reach the hospital or who do not undergo
PPCI are not included in this study, a proportion of patients
with prior myocardial infarction and diabetes mellitus may not
be included.
Strengths and Limitations
The strength of this study is the completeness of data via
link between clinical data (the Eastern Danish Heart
Registry) and Danish nationwide registries. Furthermore,
this study was well-powered as the cohort was large,
patients were enrolled consecutively, and the phenotype
was refined by enrolling only STEMI patients with VF and
distinguishing between VF before and during PPCI. Even
though data were prospectively collected, a retrospective
analysis was performed. Patients who died outside of
hospitals were not included, and the results may not be
generalizable to patients who do not survive to reach the
hospital or who do not undergo angiography.
Given that the majority of patients had an out-of-hospital
cardiac arrest (77%), quite a few variables were unaccounted
for eg, medications given in the field by the emergency
medical services personnel during resuscitation and time to
return of spontaneous circulation which may have had an
effect on the in-patient potassium levels.
Only absolute values for potassium levels were included
and not fluctuations, which may be more accurate.32 Infor-
mation on smoking status, Canadian Cardiovascular Society
grading of angina pectoris, pre-procedural left ventricular
ejection fraction, and magnesium levels in blood samples
were missing for 12%, 9%, 80%, and 95% of patients,
respectively, and thus could not be considered in the model.
QT dispersion plays an important role for the pathophysiology
of VF and/or polymorphic VT, however, information on QTc
intervals from the ECG was not available and therefore
adjustments could not be performed. Nevertheless, previ-
ously, in a subset of the cohort, no difference in QTc intervals
was measured between STEMI patients with or without VF
before PPCI.6 This is in line with the findings of others.33,34
In the sensitivity analysis, patients with hyperkalemia did
not have an increased risk of VF during PPCI possibly because
of a lack of power. Moreover, VF during PPCI may be
propagated by extensive manipulation (catheter maneuvers),
coronary spasms, and reperfusion of the coronary artery and
thus differ from the pathogenesis of VF before PPCI.
Figure 4. Potassium disturbances associated with ventricular fibrillation during PPCI among patients with STEMI who had
potassium measurements immediately before primary percutaneous coronary intervention. PPCI indicates primary percutaneous
coronary intervention; STEMI, ST-segment–elevation myocardial infarction, VF, ventricular fibrillation
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Clinical Implications
In the future, potassium measurements performed prehospital
in the ambulance by arterial blood gas analysis would allow
early detection and the opportunity for correction of potas-
sium disturbances. This may reduce the risk of VF and
subsequent death during acute ischemia. Further studies are
needed to determine if correcting potassium disturbances
among patients with STEMI will reduce the risk of VF.
Conclusions
Hypokalemia and hyperkalemia are associated with increased
risk of VF in the early phase of STEMI (before PPCI). For
hypokalemia, the association may be independent of the
measurement of potassium before or after VF.
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Table S1: International Classification of Disease (ICD) codes (ICD-10 and ICD-8). 
Comorbidity ICD-10 and ICD-8 codes 
Diabetes ICD-10: E10-14 
ICD-8: 250 
Hypertension 
 
ICD-10: I10-I15 
ICD-8: 400-403 
Hypercholesterolemia ICD-10: E780 
ICD-8: 27200, 27900 
Peripheral vascular disease ICD-10: I70, I74 
ICD-8: 440, 444 
Ischemic heart disease ICD-10: I20-I25 
ICD-8: 410-414 
Prior myocardial infarction ICD-10: I21, I22 
ICD-8: 410 
Congestive heart failure ICD-10: I42, I50, I110, I130, I132 
ICD-8: 425, 428, 4270, 4271 
Atrial fibrillation ICD-10: I48 
ICD-8: 42793, 42794 
Ischemic stroke ICD-10: I63, I64 
ICD-8: 432-434, 436 
Chronic kidney disease ICD-10: E102, E112, E132, E142, I120, N02-
N08, N11, N12, N14, N18, N19, N26, N158-
N160, N162-N164, N168, M300, M313, M319, 
M321B, Q612, Q613, Q615, Q619, T858, T859, 
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Z992 
ICD-8: 403, 404, 581-584, 25002, 40039, 59009, 
59320, 75310, 75311, 75319 
Liver disease ICD-10: K70-77, K704, K711, K766, B150, 
B160, B190 
ICD-8: 456, 571, 572 
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Table S2: Anatomical Therapeutic Chemical (ATC) classification codes. 
Pharmacotherapy ATC codes 
Diuretics (combinational) C03B, C07C, C08G, C09BA, C09DA 
Loop diuretics C03C, C03EB01, C03EB02 
Thiazides C02DA, C03A, C07B, C07D, C09XA52, 
C03EA01 
Spironolactone C03DA01 
Potassium supplements A12BA 
Renin-angiotensin-system inhibitors C09 
Beta-blockers C07, C09BX02 
Antiadrenergic drugs C02A, C02B, C02C 
Calcium channel blockers C08, C07FB, C09BB, C09DB 
Anti-diabetics A10 
Statins C10AA 
Antiarrhythmic drugs class I and III C01B 
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Table S3: A logistic regression model of risk of in-hospital ventricular fibrillation before primary 
percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. 
Variables 
 
Contrast Odds ratio 95% CI  p 
Blood samples      
Hyperkalemia Normokalemia 0.79 0.17-3.61 0.76 
Hypokalemia Normokalemia 2.23 1.60-3.11 <0.001 
Creatinine 10 µmol/L of increase 1.03 1.01-1.05 0.002 
Age     
<50 years of age ≥80 years of age 1.28 0.62-2.65 0.51 
50-80 years of age ≥80 years of age 1.70 0.93-3.12 0.08 
Sex Male vs. female 1.11 0.77-1.61 0.58 
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Table S4: Characteristics of patients with ST-segment elevation myocardial infarction (STEMI) with ventricular fibrillation during primary 
percutaneous coronary intervention (PPCI) who had potassium measurements immediately before PPCI (sensitivity analysis).  
VARIABLES 
 
Normokalemia 
3.5-5.0 mmol/l 
(n=6229) 
Hypokalemia 
<3.5 mmol/l 
(n=1593) 
p 
Hypokalemia vs. 
normokalemia 
Hyperkalemia  
>5.0 mmol/l 
(n=107) 
p 
Hyperkalemia vs. 
normokalemia 
Male sex, n (%) 4750 (76.3) 1016 (63.8) <0.001 76 (71.0) 0.25 
Median age, years [IQR] 
63.1  
[54.0, 72.3] 
63.2  
[53.7, 72.6] 
0.86 
70.3  
[61.7, 78.9] 
<0.001 
Categorical age, n (%)      
<50 years  984 (15.8) 272 (17.1) 
0.44 
6 (5.6) 
<0.001 50-80 years 4532 (72.8) 1146 (71.9) 77 (72.0) 
≥80 years 713 (11.4) 175 (11.0) 24 (22.4) 
Body mass index (BMI), 
kg/m2  
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BMI ≥25, n (%) 3036 (62.4) 788 (64.3) 0.23 44 (61.1) 0.92 
Smoking, n (%)      
Current 2866 (52.2) 667 (47.6) 
<0.001 
32 (42.7) 
0.26 Past 1379 (25.1) 330 (23.6) 23 (30.7) 
Never 1249 (22.7) 403 (28.8) 20 (26.7) 
Canadian Cardiovascular 
Society (CCS) grading of 
angina pectoris, n (%) 
     
Class I-II 703 (12.2) 173 (11.7) 
0.76 
16 (18.6) 
0.20 Class III-IV 555 (9.7) 138 (9.3) 8 (9.3) 
No angina 4487 (78.1) 1169 (79.0) 62 (72.1) 
COMORBIDITIES, n (%) 
Diabetes  743 (11.9) 139 (8.7) <0.001 38 (35.5) <0.001 
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Hypertension  1563 (25.1) 592 (37.2) <0.001 54 (50.5) <0.001 
Hypercholesterolemia  1137 (18.3) 281 (17.6) 0.60 29 (27.1) 0.027 
Peripheral vascular disease 257 (4.1) 35 (2.2) <0.001 12 (11.2) <0.001 
Family history of ischemic 
heart disease 
1663 (32.6) 431 (33.5) 0.55 18 (30.5) 0.84 
Ischemic heart disease 1280 (20.5) 308 (19.3) 0.30 36 (33.6) 0.001 
Prior myocardial infarction 782 (12.6) 161 (10.1) 0.008 27 (25.2) <0.001 
Congestive heart failure  292 (4.7) 56 (3.5) 0.05 13 (12.1) <0.001 
Atrial fibrillation 256 (4.1) 62 (3.9) 0.75 17 (15.9) <0.001 
Stroke 286 (4.6) 66 (4.1) 0.48 7 (6.5) 0.47 
Chronic kidney disease 180 (2.9) 35 (2.2) 0.15 16 (15.0) <0.001 
Liver disease 82 (1.3) 26 (1.6) 0.40 ≤3 (≤2.8) 0.94 
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OUTCOMES, n (%) 
Ventricular fibrillation 
during PPCI 
84 (1.3) 38 (2.4) 0.004 5 (4.7) 0.013 
PHARMACOTHERAPY, n (%) 
Diuretics (combinational) 244 (3.9) 167 (10.5) <0.001 4 (3.7) 1.00 
Loop diuretics 277 (4.4) 68 (4.3) 0.81 16 (15.0) <0.001 
Thiazides 331 (5.3) 230 (14.4) <0.001 8 (7.5) 0.44 
Spironolactone 61 (1.0) 8 (0.5) 0.10 7 (6.5) <0.001 
Potassium supplements 198 (3.2) 85 (5.3) <0.001 11 (10.3) <0.001 
Renin-angiotensin-system 
blockers 
1104 (17.7) 339 (21.3) 0.001 30 (28.0) 0.008 
Beta-blockers 769 (12.3) 188 (11.8) 0.58 20 (18.7) 0.07 
Anti-adrenergic drugs 53 (0.9) 16 (1.0) 0.66 0 (0.0) 0.67 
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Calcium channel blockers 684 (11.0) 303 (19.0) <0.001 19 (17.8) 0.040 
Antidiabetics 569 (9.1) 100 (6.3) <0.001 30 (28.0) <0.001 
Statins 873 (14.0) 208 (13.1) 0.34 21 (19.6) 0.13 
Antiarrhythmic drugs 7 (0.1) 0 (0.0) 0.38 ≤3 (≤2.8) <0.001 
BLOODSAMPLES 
Acute creatinine, µmol/l 
[IQR] 
77.0  
[66.0, 92.0] 
75.0  
[63.0, 88.0] 
<0.001 
132.0  
[97.0, 187] 
<0.001 
Troponin-T max, ng/L 
[IQR]  
3550  
[1380, 7470] 
3740  
[1490, 7650] 
0.09 
5615 
[1985, 12600] 
0.029 
Time from symptom to 
Troponin-T max, hours 
[IQR] 
13.9  
[9.8, 18.7] 
13.5  
[9.5, 17.8] 
0.038 
15.5  
[9.2, 21.0] 
0.38 
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Missing: BMI 22%, Smoking 12%, Family history of ischemic heart disease 19%, CCS angina 8%, Acute creatinine 7%, Troponin-T max 
21%, and Time from symptom to troponin-T max 21%. 
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Table S5: Angiographic and procedural characteristics of patients with ST-segment elevation myocardial infarction (STEMI) with ventricular 
fibrillation during primary percutaneous coronary intervention (PPCI) who had potassium measurements immediately before PPCI 
(sensitivity analysis). 
VARIABLES 
 
Normokalemia  
3.5-5.0 mmol/l  
(n=6229) 
Hypokalemia  
<3.5 mmol/l  
(n=1593) 
p 
Hypokalemia vs. 
normokalemia 
Hyperkalemia  
>5.0 mmol/l 
 (n=107) 
p 
Hyperkalemia vs. 
normokalemia 
Time from symptom onset to 
PPCI, minutes [IQR] 
191 [135-285] 151 [110-240] <0.001 240 [154-385] 0.003 
Preprocedural LVEF, n (%)      
≤35 % 243 (22.1) 72 (24.3) 0.45 19 (67.9) <0.001 
Infarct location, n (%)      
Anterior 2534 (43.4) 709 (47.6) 
0.004 
35 (39.3) 
0.51 
Non-anterior 3309 (56.6) 780 (52.4) 54 (60.7) 
Culprit lesion, n (%)      
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LAD 2666 (43.0) 757 (47.6) 
0.003 
48 (44.9) 
0.88 RCA 2644 (42.6) 633 (39.8) 43 (40.2) 
LCX 896 (14.4) 199 (12.5) 16 (15.0) 
Killip class, n (%)      
I 5502 (92.8) 1412 (92.2) 
0.56 
63 (64.9) 
<0.001 
II 251 (4.2) 77 (5.0) 8 (8.2) 
III 73 (1.2) 19 (1.2) 4 (4.1) 
IV 104 (1.8) 24 (1.6) 22 (22.7) 
Preprocedural TIMI flow, n (%)      
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TIMI 0-I 3941 (63.7) 1077 (68.3) 
<0.001 
83 (78.3) 
0.003 
TIMI II-III 2248 (36.3) 500 (31.7) 23 (21.7) 
Postprocedural TIMI-flow, n (%)      
TIMI 0-I 147 (2.4) 42 (2.7) 
0.58 
5 (4.7) 
0.22 
TIMI II-III 6030 (97.6) 1536 (97.3) 101 (95.3) 
Missing: Time from symptom to procedure 15%, LVEF 82%, and Infarct location 6%, and Killip class 5%. 
LVEF = Left ventricular ejection fraction, LAD = Left anterior descending artery, RCA = Right coronary artery, LCX = Left circumflex 
artery, TIMI = Thrombolysis in myocardial infarction. 
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Table S6: A logistic regression model of risk of ventricular fibrillation during primary 
percutaneous coronary intervention in patients with ST-segment elevation myocardial 
infarction. 
Variables 
 
Contrast Odds ratio 95% CI  p 
Blood samples      
Hyperkalemia Normokalemia 3.23 0.99-10.50 0.05 
Hypokalemia Normokalemia 1.68 1.01-2.77 0.045 
Creatinine 10 µmol/L of increase 1.00 1.00-1.01 0.13 
    Troponin-T max 1000 ng/L of increase 1.03 1.00-1.05 0.024 
Age     
<50 years of age ≥80 years of age 0.74 0.31-1.80 0.51 
50-80 years of age ≥80 years of age 0.82 0.42-1.61 0.57 
Sex Male vs. female 0.95 0.57-1.60 0.86 
Hypertension Yes vs. no 0.96 0.51-1.83 0.91 
Prior myocardial infarction Yes vs. no 0.69 0.28-1.69 0.42 
Congestive heart failure Yes vs. no 1.05 0.29-3.88 0.94 
Atrial fibrillation Yes vs. no 0.49 0.11-2.21 0.35 
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Diabetes Yes vs. no 0.47 0. 81-1.22 0.12 
Peripheral vascular disease Yes vs. no <0.01 
<0.01-
>999.99 
0.97 
Killip class >I at admission Killip class I 2.67 1.45-4.91 0.002 
Culprit  LAD vs. non-LAD 0.55 0.34-0.90 0.017 
Preprocedural TIMI-flow TIMI 0-I vs. II-III 2.98 1.55-5.72 0.001 
Loop diuretics Yes vs. no 1.27 0.41-3.94 0.68 
Combinational diuretics Yes vs. no 0.75 0.24-2.32 0.61 
Thiazides Yes vs. no 0.97 0.39-2.42 0.94 
Spironolactone Yes vs. no <0.01 
<0.01-
>999.99 
0.99 
TIMI= Thrombolysis in myocardial infarction, LAD = Left anterior descending artery. 
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Figure S1: Distribution of potassium measurements (mmol/L) immediately before primary 
percutaneous coronary intervention in patients with ST-segment elevation myocardial 
infarction. 
 
Median Mean Lower Quartile Upper Quartile Minimum Maximum Std. Dev. 
3.80 3.79 3.50 4.00 2.10 7.40 0.47 
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